Skip to content
Clinical Trials – home
FranceBack to France

Clinical trials in Nice – page 73

971 clinical trials in Nice, France across 4 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Nice at a glance
971
clinical trials
  • Research sites4
Type of trial
Recruitment status
Quick filters

971 trials in Nice

Open in trial search

Dermatitis atopic

Not recruiting

Study of Upadacitinib and Topical Corticosteroids for Adolescents and Adults with Moderate to Severe Eczema

Registered drug
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Hydrocortisone
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study on the Effects of MBS2320 for Patients with Idiopathic Pulmonary Fibrosis (IPF)

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:MBS2320
  • Sponsor:Modern Biosciences Limited

Ichthyosis+1

Not recruiting

Study on the Effects of Deucravacitinib for Adults with Inflammatory Skin Conditions (Epidermolysis Bullosa Simplex and Congenital Ichthyoses)

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Deucravacitinib
  • Sponsor:Centre Hospitalier Universitaire De Nice

Study on Enfortumab Vedotin and Pembrolizumab for Patients with Advanced Urothelial Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Enfortumab Vedotin
  • Sponsor:Seagen Inc.

Study Comparing Luspatercept and Epoetin Alfa for Treating Anemia in Patients with Low-Risk Myelodysplastic Syndrome Who Are Not Dependent on Blood Transfusions

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Epoetin Alfa
  • Sponsor:Celgene Corp.

Hidradenitis

Not recruiting

Study on Upadacitinib for Adults and Adolescents with Moderate to Severe Hidradenitis Suppurativa After Anti-TNF Therapy Failure

Investigational
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Upadacitinib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Basal cell carcinoma

Not recruiting

Study on Tirbanibulin for Treating Superficial Basal Cell Carcinoma in Patients

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Tirbanibulin
  • Sponsor:Centre Hospitalier Universitaire De Nice

Dermatitis atopic

Not recruiting

Study on the Effects of LEO 138559 for Adults with Moderate-to-Severe Atopic Dermatitis

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Humanised Igg1 Monoclonal Antibody Against Interleukin 22 Receptor Subunit Alpha
  • Sponsor:Leo Pharma A/S

Study on Brentuximab Vedotin, Lenalidomide, and Rituximab for Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Brentuximab Vedotin
  • Sponsor:Seagen Inc.

Neoplasm malignant

Not recruiting

Study of Volrustomig for Patients with Advanced Solid Tumors with Mature Tertiary Lymphoid Structures

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Volrustomig
  • Sponsor:Institut Bergonie

Rheumatoid arthritis

Not recruiting

Study Comparing Upadacitinib and Adalimumab for Adults with Moderate to Severe Rheumatoid Arthritis Not Responding to a Single TNF Inhibitor

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Adalimumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study of Lurbinectedin and Doxorubicin for First-line Treatment in Patients with Metastatic Leiomyosarcoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Filgrastim
  • Sponsor:Pharma Mar S.A.

Other cities in France

The busiest research cities in the country

All 382 cities in France

Clinical research in Nice

What the registry says about research in the country

01 Neurological Disorders

Innovative research focusing on neurodegenerative conditions and movement disorders, including trials evaluating new treatments for Amyotrophic Lateral Sclerosis and Essential Tremor.

  • ALS Treatment Development
  • Movement Disorder Therapies
  • Multiple Sclerosis Management

Studies aim to improve quality of life and slow disease progression through targeted therapeutic approaches.

02 Autoimmune Conditions

Comprehensive research into inflammatory disorders, including studies on Psoriatic Arthritis and innovative treatments for various autoimmune conditions.

  • Psoriasis Management
  • Inflammatory Disease Therapy
  • Myasthenia Gravis Treatment

Focus on developing targeted therapies and combination treatments for better disease control.

03 Oncology Research

Advanced studies in cancer treatment, particularly focusing on head and neck cancers and innovative approaches in lung cancer therapy.

  • Head and Neck Cancer Treatments
  • Neuroendocrine Carcinomas
  • Prostate Cancer Therapy

Investigating combination therapies and targeted treatments for improved patient outcomes.

04 Gastrointestinal Disorders

Groundbreaking research in inflammatory bowel diseases, including novel approaches for Crohn's Disease and Ulcerative Colitis treatment.

  • Microbiota Transplantation
  • IBD Management
  • Novel Therapeutic Approaches

Exploring innovative therapeutic strategies and microbiome-based treatments.

05 Infectious Disease Prevention

Critical research in HIV prevention and treatment, focusing on long-acting preventive medications and innovative therapeutic approaches.

  • HIV Pre-Exposure Prophylaxis
  • Long-Acting Treatments
  • Prevention Strategies

Development of new preventive measures and treatment options for at-risk populations.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.